Atai Beckley Inc. (ATAI) Stock Analysis & Investment Frameworks
Atai Beckley Inc. (ATAI) stock analysis on Invetso. Review Atai Beckley Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Atai Beckley Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Atai Beckley Inc. Key Financial Metrics
- Market Cap: $2.73B
- Revenue: $4.09M
- ROE: -353.23%
- ROIC: -61.29%
- Dividend Yield: 91.84%
About Atai Beckley Inc.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
Atai Beckley Inc. Investment Frameworks
Invetso analyzes Atai Beckley Inc. (ATAI) across the following frameworks:
- Atai Beckley Inc. 10Y Growth Potential
- Atai Beckley Inc. Scenario Analysis
- Atai Beckley Inc. Risks & Opportunities
- Atai Beckley Inc. Economic Moat
- Atai Beckley Inc. Business Model
- Atai Beckley Inc. Management
- Atai Beckley Inc. SWOT Analysis
- Atai Beckley Inc. Porter's 5 Forces
- Atai Beckley Inc. PESTLE Analysis
- Atai Beckley Inc. ESG Analysis

